$336 Million is the total value of DAFNA Capital Management LLC's 74 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 62.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SAGE | Buy | SAGE THERAPEUTICS INC | $15,685,000 | +62.1% | 181,306 | +14.5% | 4.67% | +48.4% |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $12,948,000 | +58.4% | 587,756 | +29.4% | 3.85% | +45.1% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $8,838,000 | +1.9% | 92,208 | +2.2% | 2.63% | -6.7% |
| GLPG | Buy | GALAPAGOS NVspon adr | $7,956,000 | +26.3% | 80,375 | +81.1% | 2.37% | +15.6% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $5,902,000 | +4.1% | 76,815 | +1.3% | 1.76% | -4.7% |
| TBIO | Buy | TRANSLATE BIO INC | $4,154,000 | +59.8% | 225,393 | +18.1% | 1.24% | +46.3% |
| CARA | Buy | CARA THERAPEUTICS INC | $3,956,000 | +25.7% | 261,442 | +5.7% | 1.18% | +15.1% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $3,897,000 | +16.4% | 288,440 | +1.4% | 1.16% | +6.6% |
| SAVA | New | CASSAVA SCIENCES INC | $3,069,000 | – | 450,000 | +100.0% | 0.91% | – |
| HOOK | Buy | HOOKIPA PHARMA INC | $2,773,000 | +1226.8% | 250,000 | +1033.2% | 0.82% | +1113.2% |
| KNTE | New | KINNATE BIOPHARMA INC | $2,710,000 | – | 68,121 | +100.0% | 0.81% | – |
| VERO | New | VENUS CONCEPT INC | $2,595,000 | – | 1,500,000 | +100.0% | 0.77% | – |
| VKTX | Buy | VIKING THERAPEUTICS INC | $2,567,000 | -2.2% | 455,900 | +1.1% | 0.76% | -10.4% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $2,512,000 | +177.0% | 43,916 | +46.1% | 0.75% | +153.2% |
| MREO | Buy | MEREO BIOPHARMA GROUP PLCads | $2,392,000 | +358.2% | 668,148 | +235.0% | 0.71% | +318.8% |
| MORF | New | MORPHIC HOLDING INC | $2,062,000 | – | 61,467 | +100.0% | 0.61% | – |
| MEIP | Buy | MEI PHARMA INC | $1,824,000 | -12.2% | 691,000 | +3.8% | 0.54% | -19.6% |
| NTUS | Buy | NATUS MEDICAL INC | $1,715,000 | +133.3% | 85,575 | +99.5% | 0.51% | +113.4% |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $1,693,000 | +137.1% | 16,668 | +80.6% | 0.50% | +117.2% |
| FSDC | New | FS DEVELOPMENT CORP | $1,650,000 | – | 150,000 | +100.0% | 0.49% | – |
| SCYX | New | SCYNEXIS INC | $1,530,000 | – | 200,000 | +100.0% | 0.46% | – |
| ACET | Buy | ADICET BIO INC | $1,090,000 | +35.7% | 77,577 | +14.8% | 0.32% | +24.1% |
| RVMD | New | REVOLUTION MEDICINES INC | $891,000 | – | 22,500 | +100.0% | 0.26% | – |
| PAND | New | PANDION THERAPEUTICS INC | $865,000 | – | 58,222 | +100.0% | 0.26% | – |
| ATHA | New | ATHIRA PHARMA INC | $566,000 | – | 16,531 | +100.0% | 0.17% | – |
| GNFT | New | GENFIT S Aads | $549,000 | – | 114,341 | +100.0% | 0.16% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.